Retirement Systems Of Alabama Cut Gilead Sciences (GILD) Holding; Shorts at Catasys (CATS) Raised By 1.81%

June 19, 2018 - By Mary Manson

Catasys, Inc. (NASDAQ:CATS) Logo

Catasys Inc (NASDAQ:CATS) had an increase of 1.81% in short interest. CATS’s SI was 214,000 shares in June as released by FINRA. Its up 1.81% from 210,200 shares previously. With 32,000 avg volume, 7 days are for Catasys Inc (NASDAQ:CATS)’s short sellers to cover CATS’s short positions. The SI to Catasys Inc’s float is 3.05%. The stock decreased 0.70% or $0.055 during the last trading session, reaching $7.795. About 15,789 shares traded. Catasys, Inc. (NASDAQ:CATS) has risen 55.18% since June 19, 2017 and is uptrending. It has outperformed by 42.61% the S&P500. Some Historical CATS News: ; 30/05/2018 – Catasys Launches OnTrak Solution with Second Largest Health Plan in the Nation; 30/05/2018 – CATASYS – ENTERED INTO DEAL & LAUNCHED ONTRAK PROGRAM WITH SECOND LARGEST HEALTH PLAN IN U.S; 06/03/2018 – CATASYS- REGIONAL HEALTH INSURER IN ILLINOIS ADDS ANXIETY, DEPRESSION TO ITS ONTRAK-HA PROGRAM FOR ELIGIBLE COMMERCIAL, MEDICARE MEMBERS; 14/03/2018 – CATASYS INC SAYS HAS LAUNCHED ENROLLMENT OF ITS ONTRAK-H SOLUTION WITH A NATIONAL HEALTH PLAN PARTNER; 07/03/2018 – CATASYS INC – REITERATES EXPECTATION TO REPORT ANNUAL BILLINGS OF $20.0 MLN; 15/05/2018 – CATASYS INC – COMPANY REITERATES 2018 BILLINGS GUIDANCE OF $20.0 MLN; 14/03/2018 – Catasys Launches Enrollment of OnTrak-H with Leading National Health Insurer; 04/04/2018 – CENTRAL AZUCARERA DE TARLAC – PHILIPPINE COMPETITION COMMISSION APPROVED PROPOSED ACQUISITION BY AYALA LAND OF LAND PARCELS OWNED BY CO; 06/03/2018 Catasys Announces Expansion of OnTrak-HA; 14/03/2018 – CATASYS INC SAYS ENROLLMENT OF ITS ONTRAK-H SOLUTION COMMENCING IN 16 U.S. STATES

Retirement Systems Of Alabama decreased Gilead Sciences Inc (GILD) stake by 0.69% reported in 2018Q1 SEC filing. Retirement Systems Of Alabama sold 7,241 shares as Gilead Sciences Inc (GILD)’s stock declined 17.62%. The Retirement Systems Of Alabama holds 1.04 million shares with $78.77M value, down from 1.05M last quarter. Gilead Sciences Inc now has $91.01 billion valuation. The stock increased 1.35% or $0.93 during the last trading session, reaching $69.99. About 1.60 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 4.37% since June 19, 2017 and is uptrending. It has underperformed by 8.20% the S&P500. Some Historical GILD News: ; 05/03/2018 ViiV Healthcare Announces Positive New Dolutegravir Data for the Treatment of People Living With HIV Co-lnfected With Tuberculosis; 16/04/2018 – Gilead’s Complera Rises After 1-Wk Fall, Triumeq Advances: HIV; 01/05/2018 – Gilead Sciences 1Q EPS $1.17; 15/05/2018 – U.S. Food and Drug Administration Approves Expanded Indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate); 21/05/2018 – JANSSEN PHARMACEUTICAL – VIIV HEALTHCARE WILL MARKET DOLUTEGRAVIR/RILPIVIRINE IN COUNTRIES IN EUROPEAN UNION & EUROPEAN ECONOMIC AREA; 09/04/2018 – POLL: Which of the recent large cell/gene therapy deals will work out best for the acquirer? $NVS $AVXS $CELG $GILD; 21/03/2018 – STAT Plus: Gilead patent for its Sovaldi hepatitis C drug is rejected in Ukraine; 30/04/2018 – Gilead and Verily Announce Scientific Collaboration on Immunological and Molecular Drivers of Inflammatory Diseases; 25/04/2018 – GILEAD HAD BEEN SUED BY MERCK OVER ITS HEPATITIS DRUGS; 20/04/2018 – Gilead TAF Sales Fall 1%, HIV Combo Pills Drop 2%

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on July, 25. They expect $1.42 EPS, down 43.43% or $1.09 from last year’s $2.51 per share. GILD’s profit will be $1.85 billion for 12.32 P/E if the $1.42 EPS becomes a reality. After $1.37 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts 3.65% EPS growth.

Retirement Systems Of Alabama increased Molina Healthcare Inc (NYSE:MOH) stake by 33,533 shares to 163,879 valued at $13.30M in 2018Q1. It also upped Kemper Corp Del (NYSE:KMPR) stake by 74,926 shares and now owns 138,129 shares. First Amern Finl Corp (NYSE:FAF) was raised too.

Investors sentiment increased to 0.88 in 2018 Q1. Its up 0.08, from 0.8 in 2017Q4. It increased, as 71 investors sold GILD shares while 519 reduced holdings. 114 funds opened positions while 404 raised stakes. 976.44 million shares or 0.39% more from 972.68 million shares in 2017Q4 were reported. Barclays Pcl stated it has 2.95 million shares. Acadian Asset Mngmt Limited Liability Corp holds 0% or 8,946 shares in its portfolio. Fragasso has invested 0.32% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Williams Jones And Assoc Lc has 6,041 shares for 0.01% of their portfolio. Gabelli Funds Limited holds 0.03% in Gilead Sciences, Inc. (NASDAQ:GILD) or 71,043 shares. Centurylink Investment Mgmt reported 18,962 shares. Cibc World Markets has invested 0.24% in Gilead Sciences, Inc. (NASDAQ:GILD). Daiwa Sb Invests Limited owns 480 shares for 0.01% of their portfolio. Amp Capital Ltd invested in 0.3% or 705,244 shares. Sun Life holds 0% or 450 shares. Foster & Motley Inc reported 7,403 shares. E&G Advsr Limited Partnership invested 0.88% in Gilead Sciences, Inc. (NASDAQ:GILD). Hbk Invests Limited Partnership has 349,009 shares for 0.25% of their portfolio. Capital Global Invsts, California-based fund reported 42.94 million shares. Janney Montgomery Scott Ltd Llc stated it has 197,524 shares.

Since January 2, 2018, it had 0 insider buys, and 23 selling transactions for $48.21 million activity. $434,384 worth of Gilead Sciences, Inc. (NASDAQ:GILD) was sold by Cogan John Francis. MARTIN JOHN C also sold $3.41 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Friday, June 1. Alton Gregg H had sold 30,000 shares worth $2.37 million on Thursday, January 11. 100,000 Gilead Sciences, Inc. (NASDAQ:GILD) shares with value of $8.02M were sold by Meyers James R. 5,000 shares were sold by Washington Robin L, worth $401,566. WILSON GAYLE E sold $4.68 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Friday, February 9.

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: which released: “Gilead Oncology CAR T-Cell Therapies Outlook Compelling” on June 18, 2018, also with their article: “Gilead: Growth Pick For Your Portfolio” published on June 15, 2018, published: “Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 39th Annual Global Healthcare Conference (Transcript)” on June 13, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: and their article: “Gilead: Novartis’s Kymriah Is Coming To America” published on May 24, 2018 as well as‘s news article titled: “Cramer: Gilead Is Dead Money” with publication date: June 01, 2018.

Among 31 analysts covering Gilead Sciences (NASDAQ:GILD), 22 have Buy rating, 0 Sell and 9 Hold. Therefore 71% are positive. Gilead Sciences had 132 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was maintained by Jefferies with “Buy” on Monday, June 12. Morgan Stanley maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Wednesday, May 2. Morgan Stanley has “Equal-Weight” rating and $81 target. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Equal-Weight” rating given on Thursday, May 26 by Morgan Stanley. Leerink Swann maintained the shares of GILD in report on Thursday, October 5 with “Market Perform” rating. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Outperform” rating given on Friday, October 27 by BMO Capital Markets. The firm has “Overweight” rating by PiperJaffray given on Thursday, May 31. The firm has “Buy” rating given on Wednesday, May 2 by RBC Capital Markets. As per Wednesday, September 14, the company rating was maintained by Credit Suisse. The firm has “Hold” rating given on Friday, July 21 by BMO Capital Markets. The firm has “Outperform” rating by RBC Capital Markets given on Wednesday, February 3.

Catasys, Inc. provides data analytics based specialized behavioral health management and integrated treatment services to health plans and other third party payors. The company has market cap of $124.04 million. It offers OnTrak solution to improve treatment outcomes and lower the utilization of medical and behavioral health plan services. It has a 30.45 P/E ratio. The companyÂ’s OnTrak solution includes medical and psychosocial interventions; and a proprietary Web based clinical information platform and database, psychosocial programs, and integrated care coaching services.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: